Gerresheimer starts process to sell off its business segment of technical plastics

Dusseldorf (ots) -

-Further focus on pharma & life science

Gerresheimer AG is to discontinue its business in technical
plastic systems. The business segment, which primarily
manufactures system components for suppliers to the automobile
industry, is not part of the core business of pharma & life
science. For this purpose the sale process has been started
through an international invitation for bids.

"Through the sale of the technical plastics business we are,
as previously announced, continuing our focus on the core business
of pharma & life science, "says Dr. Axel Herberg, CEO of
Gerresheimer AG.

In the segment of technical plastic systems, Gerresheimer
employs 550 people at locations in Germany, the Czech Republic and
Mexico as well as through joint ventures in Italy and Bulgaria,
manufacturing system components for suppliers to the automobile
industry. The main product focus is on vehicle electrics,
powertrain and chassis as well as interior. Sales of around EUR
70m are expected for this segment in the financial year 2008.

Gerresheimer acquired the technical plastics business in 2007
as part of the Wilden Group. While the Wilden Group's business
in medical plastic systems has today been firmly integrated in
the Gerresheimer Group's portfolio, the technical plastics segment
does not belong to Gerresheimer's core business in pharma & life
science. Through the sale, portfolio rationalisation in the Plastic
Systems Division will be completed.

In June this year, the Düsseldorf company already sold off
its consumer healthcare business, which also did not fit in with
its core business.

About Gerresheimer

Gerresheimer employs more than 10,300 people in 40 locations
in Europe, America and Asia. In the financial year 2007,
worldwide sales totalled EUR 958m. The product portfolio
ranges from pharmaceutical vials made of glass and plastic
through to complex drug-delivery systems for the pharma & life
science industry. These include sterile syringes, inhalers and
other system-based approaches for safe dosage and application of
medications. The Group enjoys a leading position in markets
which are characterised by high technical and regulatory
barriers.

Originaltext: Gerresheimer AG
digital press kits: http://www.presseportal.de/pm/9072
press kits via RSS: http://www.presseportal.de/rss/pm_9072.rss2
ISIN: DE000A0LD6E6

Pressekontakt:
Contact Press Contact Investor Relations
Burkhard Lingenberg Anke Linnartz
Director Corporate PR Director Corporate Investor
& Marketing Relations
Telephone +49 211 6181-250 Telephone +49 211 6181-314
Telefax +49 211 6181-241 Telefax +49 211 6181-121
E-mail E-mail
b.lingenberg@gerresheimer.com a.linnartz@gerresheimer.com